Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.
PLoS One. 2010 Apr 22;5(4):e10282. doi: 10.1371/journal.pone.0010282.
Antiangiogenic and anti-vascular therapies present intriguing alternatives to cancer therapy. However, despite promising preclinical results and significant delays in tumor progression, none have demonstrated long-term curative features to date. Here, we show that a single treatment session of Tookad-based vascular targeted photodynamic therapy (VTP) promotes permanent arrest of tumor blood supply by rapid occlusion of the tumor feeding arteries (FA) and draining veins (DV), leading to tumor necrosis and eradication within 24-48 h.
METHODOLOGY/PRINCIPAL FINDINGS: A mouse earlobe MADB106 tumor model was subjected to Tookad-VTP and monitored by three complementary, non-invasive online imaging techniques: Fluorescent intravital microscopy, Dynamic Light Scattering Imaging and photosensitized MRI. Tookad-VTP led to prompt tumor FA vasodilatation (a mean volume increase of 70%) with a transient increase (60%) in blood-flow rate. Rapid vasoconstriction, simultaneous blood clotting, vessel permeabilization and a sharp decline in the flow rates then followed, culminating in FA occlusion at 63.2 sec+/-1.5SEM. This blockage was deemed irreversible after 10 minutes of VTP treatment. A decrease in DV blood flow was demonstrated, with a slight lag from FA response, accompanied by frequent changes in flow direction before reaching a complete standstill. In contrast, neighboring, healthy tissue vessels of similar sizes remained intact and functional after Tookad-VTP.
CONCLUSION/SIGNIFICANCE: Tookad-VTP selectively targets the tumor feeding and draining vessels. To the best of our knowledge, this is the first mono-therapeutic modality that primarily aims at the larger tumor vessels and leads to high cure rates, both in the preclinical and clinical arenas.
抗血管生成和抗血管疗法为癌症治疗提供了很有吸引力的选择。然而,尽管有很有前景的临床前结果和肿瘤进展的显著延迟,但迄今为止,没有一种方法显示出长期的治愈特征。在这里,我们表明,单次托卡德血管靶向光动力治疗(VTP)治疗可通过快速闭塞肿瘤供养动脉(FA)和引流静脉(DV),迅速导致肿瘤血供永久停止,从而在 24-48 小时内导致肿瘤坏死和消除。
方法/主要发现:我们采用小鼠耳郭 MADB106 肿瘤模型进行托卡德-VTP 治疗,并通过三种互补的、非侵入性的在线成像技术进行监测:荧光活体显微镜、动态光散射成像和光致敏 MRI。托卡德-VTP 导致肿瘤 FA 血管扩张(平均体积增加 70%),同时血流率短暂增加(60%)。随后迅速发生血管收缩、同时发生血栓形成、血管通透性增加,血流率急剧下降,最终导致 FA 在 63.2 秒+/-1.5SEM 时闭塞。VTP 治疗 10 分钟后,这种阻塞被认为是不可逆转的。DV 血流减少,与 FA 反应略有滞后,随后在完全停止前经常改变血流方向。相比之下,托卡德-VTP 后,相邻的、大小相似的健康组织血管保持完整和功能正常。
结论/意义:托卡德-VTP 选择性地靶向肿瘤供养和引流血管。据我们所知,这是第一种主要针对较大肿瘤血管的单一治疗模式,在临床前和临床领域都能达到较高的治愈率。